The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Issues in CAR-T slot allocation in lymphoma and multiple myeloma
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, addresses the topic of CAR-T slot allocation in lymphoma and multiple myeloma. Companies are now working on organizing how to select patients for CAR-T therapy. However, the concern lies in companies not properly anticipating the increased demand that comes after approval. It is especially important to overcome this challenge now as CAR-T therapy expands into second-line treatment across multiple diseases. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
